Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects

Chronic migraine can be difficult to treat — but new research is helping identify the most effective options.

In a large new review, published today in the Annals of Internal Medicine, researchers analyzed 43 clinical trials involving adults with chronic migraine, defined as headaches on 15 or more days a month.

The st...

New Warning Labels Might Help People Cut Back On Drinking

Alcoholic beverages in the United States carry a warning label, but you’d be forgiven if they leave little impression.

In place since 1988, the label states the risks of drinking during pregnancy or while driving, along with a general notice that alcohol “may cause health problems.”

These small labels often go unnot...

New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show

A new combination drug therapy could help people with inflammatory bowel disease (IBD) for whom other medicines have stopped working, according to a pair of new studies.

The treatment combines two drugs already approved to treat inflammatory diseases, guselkubam (Tremfya) and golimumab (Simponi), researchers are reporting today at a joint ...

Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds

Ozempic can help people who are battling alcoholism, a major new clinical trial has concluded.

People with alcohol use disorder taking semaglutide (Ozempic/Wegovy) had significantly fewer heavy drinking days compared to patients assigned a placebo, researchers reported May 2 in The Lancet. 

People on semaglutide also dr...

US on the Brink of Losing Measles-free Status, Study Warns

The United States is moving quickly toward losing its status as a measles-free nation, a new study says.

The nation has missed four of seven markers set by the U.S. Centers for Disease Control and Prevention (CDC) after experts declared measles eradicated in 2000, researchers report in The Lancet.

These include a surge in me...

FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib

The U.S. Food and Drug Administration (FDA) granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib. 

This means the drug will be available for early access to those who previously received conventional treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). A healthcare provider must requ...